General overview of radioimmunotherapy of solid tumors

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 467-487

  Navarro Teulon, Isabelle ^a,b,c   Lozza, Catherine ^a,b,c   Pèlegrin, André ^a,b,c   Vivès, Eric ^a,b,c   Pouget, Jean Pierre ^a,b,c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

cancer; monoclonal antibody; radiobiology; radioimmunotherapy; radionuclide; solid tumor

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTIN; FLUOROURACIL; GALLIUM 67; GEMCITABINE; GIRENTUXIMAB; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33; MONOCLONAL ANTIBODY CA4P; MONOCLONAL ANTIBODY CB72.3; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CICB M3; MONOCLONAL ANTIBODY HMN14; MONOCLONAL ANTIBODY HUA33; MONOCLONAL ANTIBODY MG250; MUCIN 1; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; B CELL LYMPHOMA; BONE MARROW TOXICITY; BRAIN CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DOSIMETRY; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; ISOTOPE LABELING; KIDNEY CANCER; MATHEMATICAL MODEL; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 84877301430     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.34     Document Type: Review

References (214)

1. Denardo SJ, Denardo GL, O'Grady LF et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int. J. Cancer Suppl. 3, 96-101 (1988).
2. Press OW, Eary JF, Appelbaum FR et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329(17), 1219-1224 (1993).
3. Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329(7), 459-465 (1993).
4. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin. Nucl. Med. 40(2), 122-135 (2010).
5. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
6. Pouget JP, Navarro-Teulon I, Bardies M et al. Clinical radioimmunotherapy - the role of radiobiology. Nat. Rev. Clin. Oncol. 8(12), 720-734 (2011).
7. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117(1), 45-52 (2011).
8. Denardo SJ, O'Grady LF, Richman CM et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 17(3B), 1745-1751 (1997).
9. Denardo SJ, Kramer EL, O'Donnell RT et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a Phase I clinical trial. J. Nucl. Med. 38(8), 1180-1185 (1997).
10. Richman CM, Denardo SJ, O'Donnell RT et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11(16), 5920-5927 (2005).
11. Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24(4), 571-578 (2006).
12. Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24(1), 115-122 (2006).
13. Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Bone marrow dosimetry using 124I-PET. J. Nucl. Med. 53(4), 615-621 (2012).
14. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA et al. (124)I-huA33 antibody PET of colorectal cancer. J. Nucl. Med. 52(8), 1173-1180 (2011).
15. Gonzalez GP, Garcia IG, Gonzalez JG et al. Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother. Radiopharm. 26(3), 353-363 (2011).
16. Salaun PY, Campion L, Bournaud C et al. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J. Nucl. Med. 53(8), 1185-1192 (2012).
17. Jensen AD, Krauss J, Potthoff K et al. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT. BMC Cancer 11, 182 (2011).
18. Stillebroer AB, Boerman OC, Desar IM et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. pii: S0302- 2838(12)00959-1 (2012).
19. Stillebroer AB, Zegers CM, Boerman OC et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J. Nucl. Med. 53(1), 82-89 (2012).
20. Gulec SA, Cohen SJ, Pennington KL et al. Treatment of advanced pancreatic carcinoma with 90Y-xlivatuzumab tetraxetan: a Phase I single-dose escalation trial. Clin. Cancer Res. 17(12), 4091-4100 (2011).
21. Ocean AJ, Pennington KL, Guarino MJ et al. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a Phase 1 trial. Cancer 118(22), 5497-5506 (2012).
22. Allen BJ, Singla AA, Rizvi SM et al. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 3(9), 1041-1050 (2011).
23. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
24. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23(9), 1073-1078 (2005).
25. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46(Suppl. 1), S115-S127 (2005).
26. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80(4), 863-878 (1992).
27. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q. J. Nucl. Med. Mol. Imaging 48(4), 251-257 (2004).
28. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 312(5995), 643-646 (1984).
29. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA 81(21), 6851-6855 (1984).
30. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069), 522-525 (1986).
31. Laffly E, Sodoyer R. Monoclonal and recombinant antibodies, 30 years after. Hum. Antibodies 14(1-2), 33-55 (2005).
32. Gruber R, Van Haarlem LJ, Warnaar SO, Holz E, Riethmuller G. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 60(7), 1921-1926 (2000).
33. Mccafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301), 552-554 (1990).
34. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 23(9), 1117-1125 (2005).
35. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
36. Koshkaryev A, Sawant R, Deshpande M, Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv. Drug Deliv. Rev. 65(1), 24-35 (2012).
37. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 12, 14 (2012).
38. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat. Rev. Cancer 12(4), 278-287 (2012).
39. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol. 34(7), 757-778 (2007).
40. Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Semin. Nucl. Med. 31(4), 330-341 (2001).
41. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med. 27(9), 1490-1497 (1986).
42. Koppe MJ, Bleichrodt RP, Soede AC et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177) Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J. Nucl. Med. 45(7), 1224-1232 (2004).
43. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med. 36(10), 1902-1909 (1995).
44. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J. Nucl. Med. 40(8), 1337-1341 (1999).
45. Konijnenberg M, Melis M, Valkema R, Krenning E, De Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J. Nucl. Med. 48(1), 134-142 (2007).
46. Rosenblat TL, Mcdevitt MR, Mulford DA et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213- lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16(21), 5303-5311 (2010).
47. Jurcic JG, Larson SM, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100(4), 1233-1239 (2002).
48. Andersson H, Cederkrantz E, Back T et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab́)2 - a Phase I study. J. Nucl. Med. 50(7), 1153-1160 (2009).
49. McDevitt MR, Sgouros G, Finn RD et al. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25(9), 1341-1351 (1998).
50. Allen BJ, Raja C, Rizvi S, Song EY, Graham P. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys. Med. Biol. 52(13), L15-L19 (2007).
51. Sgouros G, Roeske JC, McDevitt MR et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51(2), 311-328 (2010).
52. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63(16), 5084-5090 (2003).
53. Yong K, Brechbiel MW. Towards translation of (212)Pb as a clinical therapeutic; getting the lead in. Dalton Trans. 40(23), 6068-6076 (2011).
54. Kassis AI. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat. Prot. Dosimetry 143(2-4), 241-247 (2011).
55. Sastry KS, Rao DV. Dosimetry of low energy electrons. In: Physics of Nuclear Medicine: Recent Advances. Rao DV, Chandra R, Graham MC (Eds). American Institute of Physics, MD, USA, 169-208 (1984).
56. Santoro L, Boutaleb S, Garambois V et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J. Nucl. Med. 50(12), 2033-2041 (2009).
57. Boudousq V, Ricaud S, Garambois V et al. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J. Nucl. Med. 51(11), 1748-1755 (2010).
58. Pouget JP, Santoro L, Raymond L et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat. Res. 170(2), 192-200 (2008).
59. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc. Natl Acad. Sci. USA 99(21), 13765-13770 (2002).
60. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 972-975 (2004).
61. Welt S, Scott AM, Divgi CR et al. Phase I/II study of iodine 125I-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol. 14(6), 1787-1797 (1996).
62. Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J. Nucl. Med. 52(5), 830-838 (2011).
63. Stewart JS, Hird V, Snook D et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int. J. Radiat. Oncol. Biol. Phys. 16(2), 405-413 (1989).
64. Stewart JS, Hird V, Snook D, Sullivan M, Myers MJ, Epenetos AA. Intraperitoneal 131I-and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int. J. Cancer Suppl. 3, 71-76 (1988).
65. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van Den Bogaert W. Fractionation parameters for human tissues and tumors. Int. J. Radiat. Biol. 56(5), 701-710 (1989).
66. Brenner DJ, Hall EJ. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 20(1), 181-190 (1991).
67. Tempero M, Leichner P, Baranowska- Kortylewicz J et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a Phase I trial. Clin. Cancer Res. 6(8), 3095-3102 (2000).
68. Sharkey RM, Goldenberg DM, Murthy S et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 71(6), 2082-2096 (1993).
69. Dewaraja YK, Schipper MJ, Roberson PL et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J. Nucl. Med. 51(7), 1155-1162 (2010).
70. Denardo G, Denardo S. Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm. Semin. Nucl. Med. 40(2), 136-144 (2010).
71. Linden O, Hindorf C, Cavallin-Stahl E et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti- CD22 monoclonal antibody, epratuzumab. Clin. Cancer Res. 11(14), 5215-5222 (2005).
72. Bardies M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? Q. J. Nucl. Med. Mol. Imaging 55(1), 5-20 (2011).
73. Konijnenberg M. From imaging to dosimetry and biological effects. Q. J. Nucl. Med. Mol. Imaging 55(1), 44-56 (2011).
74. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: bystander and low dose rate effects: are these relevant to radionuclide therapy? J. Nucl. Med. 48(10), 1683-1691 (2007).
75. Paillas S, Boudousq V, Piron B et al. Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane. Nucl. Med. Biol. pii: S0969-8051(13)00017-6 (2013).
76. Murtha AD. Review of low-dose rate radiobiology for clinicians. Semin. Radiat. Oncol. 10(2), 133-138 (2000).
77. Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D'Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q. J. Nucl. Med. Mol. Imaging 55(2), 205-221 (2011).
78. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18(5), 1261-1269 (1990).
79. Knox SJ, Goris ML, Tempero M et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6(2), 406-414 (2000).
80. Wilder RB, Denardo GL, Sheri S, Fowler JF, Wessels BW, Denardo SJ. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. Eur. J. Nucl. Med. 23(8), 953-957 (1996).
81. Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(Suppl. 12), 2519-2528 (1997).
82. Roberson PL, Buchsbaum DJ. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Res. 55(Suppl. 23), S5811-S5816 (1995).
83. Flynn AA, Pedley RB, Green AJ et al. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear - quadratic formulation. Int. J. Radiat. Biol. 77(4), 507-517 (2001).
84. Milenic DE, Garmestani K, Brady ED et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13(6), 1926-1935 (2007).
85. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int. J. Cancer 97(3), 386-392 (2002).
86. Gold DV, Modrak DE, Schutsky K, Cardillo TM. Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft. Int. J. Cancer 109(4), 618-626 (2004).
87. Ruan S, O'Donoghue JA, Larson SM et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J. Nucl. Med. 41(11), 1905-1912 (2000).
88. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 24(4), 539-567 (2005).
89. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin. Cancer Res. 13(5), 1374-1382 (2007).
90. Forero A, Weiden PL, Vose JM et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104(1), 227-236 (2004).
91. Denardo SJ, Richman CM, Albrecht H et al. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin. Cancer Res. 11(19 Pt 2), S7187-S7194 (2005).
92. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24(5), 823-834 (2006).
93. Kraeber-Bodere F, Rousseau C, Bodet-Milin C et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a Phase I optimization clinical trial. J. Nucl. Med. 47(2), 247-255 (2006).
94. Shen S, Forero A, Lobuglio AF et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46(4), 642-651 (2005).
95. Chatal JF, Campion L, Kraeber-Bodere F et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J. Clin. Oncol. 24(11), 1705-1711 (2006).
96. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl Acad. Sci. USA 86(10), 3833-3837 (1989).
97. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy 3(3), 349-370 (2011).
98. Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr. Opin. Biotechnol. 22(6), 882-887 (2011).
99. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23(9), 1126-1136 (2005).
100. Nelson AL. Antibody fragments: hope and hype. MAbs 2(1), 77-83 (2010).
101. Yazaki PJ, Wu AM, Tsai SW et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem. 12(2), 220-228 (2001).
102. Sauer S, Erba PA, Petrini M et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113(10), 2265-2274 (2009).
103. Essler M, Gartner FC, Neff F et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging 39(4), 602-612 (2012).
104. Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng. Des. Sel. 17(4), 293-304 (2004).
105. Osbourn JK, Field A, Wilton J et al. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 2(3), 181-196 (1996).
106. Adams GP, Schier R, Mccall AM et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61(12), 4750-4755 (2001).
107. Sabbatini P, Spriggs DR. Consolidation for ovarian cancer in remission. J. Clin. Oncol. 24(4), 537-539 (2006).
108. Oei AL, Verheijen RH, Seiden MV et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer 120(12), 2710-2714 (2007).
109. Alvarez RD, Huh WK, Khazaeli MB et al. A Phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8(9), 2806-2811 (2002).
110. Shen S, Forero A, Meredith RF, Lobuglio AF. Biodistribution and dosimetry of In-111/Y-90-HuCC49DeltaCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. Cancer Biother. Radiopharm. 26(1), 127-133 (2011).
111. Zalutsky MR, Reardon DA, Akabani G et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49(1), 30-38 (2008).
112. Akabani G, Reardon DA, Coleman RE et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a Phase II study. J. Nucl. Med. 46(6), 1042-1051 (2005).
113. Burton ER, Libutti SK. Targeting TNF-alpha for cancer therapy. J. Biol. 8(9), 85 (2009).
114. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4(10), 806-813 (2004).
115. Padera TP, Stoll BR, Tooredman JB, Capen D, Di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 427(6976), 695 (2004).
116. Itzkowitz SH, Shi ZR, Kim YS. Heterogeneous expression of two oncodevelopmental antigens, CEA and SSEA-1, in colorectal cancer. Histochem. J. 18(4), 155-163 (1986).
117. Zhang Y, Pastan I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14(24), 7981-7986 (2008).
118. Kaanders JH, Bussink J, Van Der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin. Radiat. Oncol. 14(3), 233-240 (2004).
119. Wong JY, Chu DZ, Williams LE et al. A Phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother. Radiopharm. 21(2), 88-100 (2006).
120. Demaria S, Bhardwaj N, Mcbride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 63(3), 655-666 (2005).
121. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
122. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am. J. Pathol. 162(6), 1747-1757 (2003).
123. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
124. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47(12), 3039-3051 (1987).
125. Jain RK. Barriers to drug delivery in solid tumors. Sci. Am. 271(1), 58-65 (1994).
126. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48(24 Pt 1), 7022-7032 (1988).
127. Kinuya S, Yokoyama K, Yamamoto W et al. Short-period-induced hypertension could improve tumor-to-nontumor ratios of radiolabeled monoclonal antibody. Nucl. Med. Biol. 24(6), 547-551 (1997).
128. Noguchi A, Takahashi T, Yamaguchi T et al. Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J. Cancer Res. 83(3), 240-243 (1992).
129. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6), 553-563 (2004).
130. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64(11), 3731-3736 (2004).
131. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66(3), 1434-1445 (2006).
132. Kraeber-Bodere F, Bodet-Milin C, Niaudet C et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. J. Nucl. Med. 51(4), 624-631 (2010).
133. Ashrafi SA, Hosseinimehr SJ, Varmira K, Abedi SM. Radioimmunotherapy with 131I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor. Cancer Biother. Radiopharm. 27(7), 420-425 (2012).
134. Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent Results Cancer Res. 180, 201-216 (2010).
135. Nagengast WB, De Vries EG, Hospers GA et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48(8), 1313-1319 (2007).
136. Abbas Rizvi SM, Song EY, Raja C et al. Preparation and testing of bevacizumab radioimmunoconjugates with bismuth-213 and bismuth-205/bismuth-206. Cancer Biol. Ther. 7(10), 1547-1554 (2008).
137. Pink DB, Schulte W, Parseghian MH, Zijlstra A, Lewis JD. Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery. PLoS ONE 7(3), e33760 (2012).
138. Moschetta M, Pretto F, Berndt A et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 72(7), 1814-1824 (2012).
139. Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumour Biol. 33(6), 2019-2029 (2012).
140. Kinuya S, Yokoyama K, Hiramatsu T et al. Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts. Cancer Lett. 140(1-2), 209-218 (1999).
141. Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43(1), 33-56 (2002).
142. Wust P, Hildebrandt B, Sreenivasa G et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 3(8), 487-497 (2002).
143. Kinuya S, Yokoyama K, Michigishi T, Tonami N. Optimization of radioimmunotherapy interactions with hyperthermia. Int. J. Hyperthermia 20(2), 190-200 (2004).
144. Hauck ML, Zalutsky MR. The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. Clin. Cancer Res. 4(9), 2071-2077 (1998).
145. Sapareto SA, Hopwood LE, Dewey WC, Raju MR, Gray JW. Effects of hyperthermia on survival and progression of Chinese hamster ovary cells. Cancer Res. 38(2), 393-400 (1978).
146. Hauck ML, Zalutsky MR. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: application of the thermal equivalency equation. Int. J. Hyperthermia 21(1), 13-27 (2005).
147. Hauck ML, Zalutsky MR. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part I: timing of injection relative to hyperthermia. Int. J. Hyperthermia 21(1), 1-11 (2005).
148. Mittal BB, Zimmer MA, Sathiaseelan V et al. Phase I/II trial of combined 131I anti- CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma. Cancer 78(9), 1861-1870 (1996).
149. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 5(4), 321-327 (2005).
150. Khaibullina A, Jang BS, Sun H et al. Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J. Nucl. Med. 49(2), 295-302 (2008).
151. Poff JA, Allen CT, Traughber B et al. Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology 248(2), 485-491 (2008).
152. Wang S, Shin IS, Hancock H et al. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J. Control. Release 162(1), 218-224 (2012).
153. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285(5433), 1569-1572 (1999).
154. Chen P, Wang J, Hope K et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J. Nucl. Med. 47(5), 827-836 (2006).
155. Mclarty K, Cornelissen B, Cai Z et al. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J. Nucl. Med. 50(8), 1340-1348 (2009).
156. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J. Nucl. Med. 48(8), 1357-1368 (2007).
157. Niesner U, Halin C, Lozzi L et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug. Chem. 13(4), 729-736 (2002).
158. Jain M, Chauhan SC, Singh AP, Venkatraman G, Colcher D, Batra SK. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res. 65(17), 7840-7846 (2005).
159. Zalutsky MR, Xu FJ, Yu Y et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl. Med. Biol. 26(7), 781-790 (1999).
160. Cornelissen B, Darbar S, Hernandez R et al. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy. J. Nucl. Med. 52(5), 776-783 (2011).
161. Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr. Drug Deliv. 8(1), 26-44 (2011).
162. Pfost B, Seidl C, Autenrieth M et al. Intravesical alpha- radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med. 50(10), 1700-1708 (2009).
163. Niu G, Sun X, Cao Q et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin. Cancer Res. 16(7), 2095-2105 (2010).
164. Wong KJ, Baidoo KE, Nayak TK, Garmestani K, Brechbiel MW, Milenic DE. In vitro and in vivo pre-clinical analysis of a F(ab́)(2) fragment of panitumumab for molecular imaging and therapy of HER1 positive cancers. EJNMMI Res. 1(1), pii: 1 (2011).
165. Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14(16), 5108-5115 (2008).
166. Palm S, Back T, Claesson I et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 69(2), 572-579 (2007).
167. Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE 7(8), e42345 (2012).
168. Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE. Pre-clinical assessment of lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease.
169. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 432(7015), 332-337 (2004).
170. Fischer E, Chaitanya K, Wuest T et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin. Cancer Res. 18(22), 6208-6218 (2012).
171. Cheng J, Ekberg T, Engstrom M et al. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Laryngoscope 117(6), 1013-1018 (2007).
172. Beck R, Seidl C, Pfost B et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci. 98(8), 1215-1222 (2007).
173. Sato N, Hassan R, Axworthy DB et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J. Nucl. Med. 46(7), 1201-1209 (2005).
174. Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. Cancer 116(Suppl. 4), 1067-1074 (2010).
175. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin. Cancer Res. 11(19 Pt 2), S7070-S7074 (2005).
176. Meyer T, Gaya AM, Dancey G et al. A Phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 15(13), 4484-4492 (2009).
177. Ychou M, Azria D, Menkarios C et al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab́)2 after resection of liver metastases from colorectal cancer. Clin. Cancer Res. 14(11), 3487-3493 (2008).
178. Wong JY, Thomas GE, Yamauchi D et al. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. J. Nucl. Med. 38(12), 1951-1959 (1997).
179. Wong JY, Shibata S, Williams LE et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin. Cancer Res. 9(16 Pt 1), 5842-5852 (2003).
180. Wong JY, Somlo G, Odom-Maryon T et al. Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin. Cancer Res. 5(Suppl. 10), S3224-S3231 (1999).
181. Shibata S, Raubitschek A, Leong L et al. A Phase I study of a combination of yttrium- 90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin. Cancer Res. 15(8), 2935-2941 (2009).
182. Juweid ME, Hajjar G, Stein R et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J. Nucl. Med. 41(1), 93-103 (2000).
183. Yu B, Carrasquillo J, Milenic D et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J. Clin. Oncol. 14(6), 1798-1809 (1996).
184. Ychou M, Ricard M, Lumbroso J et al. Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. Eur. J. Cancer 29A(8), 1105-1111 (1993).
185. Sultana A, Shore S, Raraty MG et al. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 9, 66 (2009).
186. Casey JL, Napier MP, King DJ et al. Tumour targeting of humanised cross-linked divalent- Fab́ antibody fragments: a clinical Phase I/II study. Br. J. Cancer 86(9), 1401-1410 (2002).
187. Juweid ME, Hajjar G, Swayne LC et al. Phase I/II trial of 131I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85(8), 1828-1842 (1999).
188. Juweid M, Sharkey RM, Alavi A et al. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti- CEA monoclonal antibody. J. Nucl. Med. 38(2), 257-260 (1997).
189. Behr TM, Sharkey RM, Juweid ME et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. Nucl. Med. 38(6), 858-870 (1997).
190. Liersch T, Meller J, Kulle B et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J. Clin. Oncol. 23(27), 6763-6770 (2005).
191. Behr TM, Liersch T, Greiner-Bechert L et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94(Suppl. 4), 1373-1381 (2002).
192. Tempero M, Leichner P, Dalrymple G et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a Phase I trial. J. Clin. Oncol. 15(4), 1518-1528 (1997).
193. Robert F, Busby EM, Lobuglio AF. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity. Cancer Biother. Radiopharm. 18(3), 317-325 (2003).
194. Meredith RF, Khazaeli MB, Liu T et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J. Nucl. Med. 33(9), 1648-1653 (1992).
195. Meredith RF, Khazaeli MB, Macey DJ et al. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5(Suppl. 10), S3254-S3258 (1999).
196. Meredith RF, Khazaeli MB, Plott WE et al. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin. Cancer Res. 2(11), 1811-1818 (1996).
197. Chong G, Lee FT, Hopkins W et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin. Cancer Res. 11(13), 4818-4826 (2005).
198. Scott AM, Lee FT, Jones R et al. A Phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 11(13), 4810-4817 (2005).
199. Welt S, Divgi CR, Real FX et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a Phase I study of monoclonal antibody A33. J. Clin. Oncol. 8(11), 1894- 1906 (1990).
200. Divgi CR, O'Donoghue JA, Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J. Nucl. Med. 45(8), 1412-1421 (2004).
201. Oosterwijk E, Bander NH, Divgi CR et al. Antibody localization in human renal cell carcinoma: a Phase I study of monoclonal antibody G250. J. Clin. Oncol. 11(4), 738-750 (1993).
202. Divgi CR, Bander NH, Scott AM et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. 4(11), 2729-2739 (1998).
203. Brouwers AH, Mulders PF, De Mulder PH et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23(27), 6540-6548 (2005).
204. Riva P, Franceschi G, Frattarelli M et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin. Cancer Res. 5(Suppl. 10), S3275-S3280 (1999).
205. Grana C, Chinol M, Robertson C et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer 86(2), 207-212 (2002).
206. Li L, Quang TS, Gracely EJ et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J. Neurosurg. 113(2), 192-198 (2010).
207. Snelling L, Miyamoto CT, Bender H et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14(2), 111-114 (1995).
208. Hird V, Maraveyas A, Snook D et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 68(2), 403-406 (1993).
209. Morris MJ, Divgi CR, Pandit-Taskar N et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11(20), 7454-7461 (2005).
210. Morris MJ, Pandit-Taskar N, Divgi CR et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res. 13(9), 2707-2713 (2007).
211. Vallabhajosula S, Goldsmith SJ, Hamacher KA et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med. 46(5), 850- 858 (2005).
212. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin. Cancer Res. 11(19 Pt 2), S7195-S7200 (2005).
213. Meredith RF, Khazaeli MB, Plott WE et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. Nucl. Med. 36(12), 2229-2233 (1995).
214. Kramer K, Humm JL, Souweidane MM et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra- Ommaya 131I-3F8. J. Clin. Oncol. 25(34), 5465-5470 (2007).